Vargatef in Addition to First Line Chemotherapy With Interval Debulking Surgery in Patients With Ovarian Cancer (CHIVA)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01583322|
Recruitment Status : Completed
First Posted : April 24, 2012
Last Update Posted : March 17, 2016
Patients with extensive and bulky disease are often those whose initial surgery is delayed after 3 or 4 cycles of neo-adjuvant chemotherapy.
In that case, there is, indeed, some concern to administer bevacizumab during the chemotherapy surrounding the interval debulking surgery due to the long half life (14- 21 days) of this monoclonal antibody and the interference of anti angiogenic agents with wound healing.
Vargatef® (Nintedanib) might offer a better alternative to bevacizumab in the neo-adjuvant setting. Vargatef® (Nintedanib) has a much shorter half-life of 7 to 19 hours. Preliminary experience in cancer did not show a trend for increased incidence of fistula or bowel perforation. For more details please refer to the investigator drug brochure for Vargatef® (Nintedanib).
This trial will compare progression-free survival and surgical complications of 188 patients with FIGO stage IIIC/IV treated in first line with either neo-adjuvant chemotherapy (carboplatin & paclitaxel) and interval debulking surgery or the same treatment + Vargatef® (Nintedanib).
|Condition or disease||Intervention/treatment||Phase|
|Ovarian Cancer||Drug: vargatef Drug: placebo||Phase 2|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||188 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Double (Participant, Investigator)|
|Official Title:||Randomized Double Blind Placebo-controlled Phase II Trial of Vargatef® (Nintedanib) in Addition to First Line Chemotherapy With Interval Debulking Surgery in Patients With Adenocarcinoma of the Ovary, the Fallopian Tube or Serous Adenocarcinoma of the Peritoneum|
|Study Start Date :||June 2012|
|Actual Primary Completion Date :||May 2015|
|Actual Study Completion Date :||March 2016|
U.S. FDA Resources
400 mg (200 mg twice daily) Route of administration= oral Twice daily (to be swallowed unchewed with a glass of water of about 250 mL. If taken twice the dose interval should be of around 12 hours at the same times every day, usually in the morning and the evening after food intake).
Continuous daily dosing until progression of disease or until criteria for interruption of treatment are met, no intake of Vargatef® (Nintedanib) on days of paclitaxel and carboplatin administration. The maximum time on monotherapy is 2 years.
|Placebo Comparator: placebo||
Contains 0 mg of Vargatef® (Nintedanib) in capsules matching 100 mg and 150 mg of Vargatef® (Nintedanib) Route of administration: oral Twice daily (to be swallowed unchewed with a glass of water of about 250 mL. If taken twice the dose interval should be of around 12 hours at the same times every day, usually in the morning and the evening after food intake).
Continuous daily dosing until progression of disease or until criteria for interruption of treatment is met, no intake of placebo on days of paclitaxel and carboplatin administration.
The maximum time on monotherapy is 2 years.
- Median Progression-free Survival (PFS) in each study arm [ Time Frame: average of 18 months ]
- Response rate [ Time Frame: 2 months after beginning of treatment ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01583322
|Centre Paul Papin|
|Institut Ste Catherine|
|Polyclinique Bordeaux Nord|
|centre Francois baclesse|
|Centre Georges François leclerc|
|Centre Oscar Lambret|
|Lyon, France, 69000|
|Centre Léon bérard|
|Centre Alexis Vautrin|
|Centre Catherine de Sienne|
|Centre Hospitalier Régional|
|Centre Hospitalier Lyon-sud|
|Pierre-Bénite, France, 69495|
|Institut Jean Godinot|
|Centre Henri Becquerel|
|Clinique Armoricaine de Radiologie|
|Saint Brieuc, France|
|ICO René Gauducheau|
|St Herblain, France|
|Centre Claudius Régaud|
|Toulouse, France, 31052|
|Principal Investigator:||Gwénaël Ferron, MD||Institut Claudius Régaud|